Matrix stiffness regulates glucose-6-phosphate dehydrogenase expression to mediate sorafenib resistance in hepatocellular carcinoma through the ITGB1-PI3K/AKT pathway
Abstract Sorafenib is an antiangiogenic and antiproliferative chemotherapeutic drug that plays a crucial role in the treatment of patients with advanced hepatocellular carcinoma (HCC). However, resistance to sorafenib greatly limits its therapeutic efficacy. This highlights the importance of determi...
Saved in:
| Main Authors: | Ruimei Ren, Shan Zhang, Zhan Peng, Xiaomeng Ji, Hao Song, Qiuxiao Wang, Xiangyin Sun, Huiyu Wang, Yinying Dong |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2025-07-01
|
| Series: | Cell Death and Disease |
| Online Access: | https://doi.org/10.1038/s41419-025-07842-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
ITGA5 and ITGB1 contribute to Sorafenib resistance by promoting vasculogenic mimicry formation in hepatocellular carcinoma
by: Ying Shi, et al.
Published: (2023-02-01) -
PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma
by: Pusen Wang, et al.
Published: (2020-10-01) -
Multi-spatial-attention U-Net: a novel framework for automated gallbladder segmentation on CT images
by: Henan Lou, et al.
Published: (2025-05-01) -
Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma
by: Muhammad W. Saif, et al.
Published: (2011-01-01) -
Bibliometric study on the utilization of sorafenib in hepatocellular carcinoma
by: Wenjun Meng, et al.
Published: (2024-12-01)